A 62-year-old man decided to
get vaccinated 217 times against covid
, despite doctors' advice not to do so.
Scientists investigated
how his body reacted
to it and the result surprised everyone.
According to
The Lancet Infectious Diseases
magazine in its latest issue, the vaccines were purchased and administered
privately over a period of 29 months.
The man born in Germany,
whose identity was not revealed
, became a subject of study given what the coronavirus pandemic left behind and certain reasonable fears.
How the man reacted to 217 doses of the covid vaccine
"We learned about his case through newspaper articles. We then contacted him and invited him to undergo various tests in Erlangen," explains
Kilian Schober
from the
University of Erlangen-Nuremberg.
So experts from the German university's microbiology department began taking
blood and saliva samples.
"We were able to take blood samples ourselves when the man received another vaccine during the study at his insistence. This is how we determined exactly
how the immune system reacts to the vaccine
," added the former scientist.
Scientists studied the case of the German who was vaccinated 217 times.
Schober and his team were concerned that overstimulating the immune system with repeated doses
could cause cell fatigue.
However, no evidence was found
of this situation in the man and
there were no signs that he had ever been infected with covid.
In any case, it is worth noting, the experts highlighted that
they do not support a person being vaccinated so many times
as a strategy to improve immunity in the case of this pandemic that affected the world.
Insufficient results
The results of the tests carried out on the German were
insufficient to draw far-reaching conclusions
, much less to make recommendations for the public, the EFE agency warns.
Scientists did not detect that the man had ever been infected with covid.
Illustrative photo AP
Thus, from the study center, they warn: "Current research indicates that
a three-dose vaccine
, along with periodic complementary vaccines for vulnerable groups, remains the preferred approach."